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Abstract
Background: Carbohydrates embedded in the plasma membrane are one of the main actors
involved in the communication of cells with the microenvironment. Neuraminic sialic acids are
glycocalyx sugars that play important roles in the modulation of malignant cell behaviour. N-
glycolylneuraminic acid (NeuGc) is synthesized by the cytidine monophospho-N-acetylneuraminic
acid hydroxylase (CMAH), an enzyme expressed in all mammals except humans. In mice, this sugar
is synthesized in several somatic tissues.
Methods: We used the B16 melanoma and F3II mammary carcinoma mouse tumor cell lines. By
CMAH directed RT-PCR and NeuGc detection with the specific anti-NeuGc-GM3 antibody 14F7
we evaluated enzyme and ganglioside expression in tumor cells, respectively. Expression of NeuGc-
GM3 ganglioside was reached by in vitro incubation with NeuGc-rich bovine submaxillary mucin and
evaluated by slot-blot and immunohistochemistry assays using the 14F7 antibody. Tumor cells
treated with mucin or purified NeuGc were injected s.c. and i.v. in syngeneic mice to evaluate
tumor and metastatic growth.
Results: In the present work we demonstrated the absence of expression of CMAH enzyme in
B16 melanoma and F3II mammary carcinoma cells. In vitro incubation of these NeuGc-negative cells
with NeuGc-rich mucin increased the presence of NeuGc in cell membranes for at least 48-72 h,
as a component of the GM3 ganglioside. Preincubation with NeuGc-rich mucin reduced tumor
latency and increased the metastatic potential of tumor cells in syngeneic animals. Similar results
were obtained when cells were incubated with purified NeuGc alone.
Conclusion: Our results indicate that B16 and F3II mouse tumor cell lines do not express NeuGc
in cell membranes but they are able to incorporate NeuGc from an exogenous source, contributing
to the malignant phenotype of melanoma and mammary carcinoma cells.
Background
The glycocalyx is composed of a broad variety of sugars
that play a crucial role in the communication of cells with
the microenvironment. Neuraminic sialic acids are 9-car-
bon sugars typically found in the glycocalyx that take part
in the modulation of malignant cell behaviour [1,2]. They
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are usually found as a terminal component of different
membrane glycoconjugates, such as glycoproteins or gly-
colipids. Major examples are mucins and gangliosides,
both implicated in the modulation of cell behaviour [3,4].
The most common sialic acids in mammals are N-acetyl-
neuraminic (NeuAc) and N-glycolylneuraminic (NeuGc)
acids. The only structural difference between them con-
sists of a single oxygen atom at the C-5 position of NeuGc
catalyzed by the cytidine monophospho-N-acetyl-
neuraminic acid hydroxylase (CMAH) [5]. While NeuGc
is expressed in most somatic mouse cells, there is nearly
no information regarding its expression in mouse cancer
tissues [6]. Few reports suggest a null presence of this
sugar in murine malignant cells.
Mucins are large molecular weight glycoproteins charac-
terized by carbohydrate sugars attached via O-glycosidic
linkages to serine or threonine, synthesized by a variety of
secretory epithelial tissues as membrane-bound or
secreted proteins. Characteristically, mucins present sialic
acids as part of their sugar repertoire. In particular, the
minor type of the bovine submaxillary mucin (BSM)
presents a high concentration of NeuGc in its arborization
[7].
It is well described that cells can process exogenous sialic
acids from the extracellular environment and use them for
their own glycoconjugates [8,9]. In this work we explored
the impact of exogenous NeuGc incorporation by NeuGc-
rich BSM or purified NeuGc in vitro incubation in the
malignant behaviour of B16 melanoma and F3II mam-
mary carcinoma mouse tumor cell lines.
Methods
Tumor cells
B16F0 and F3II cell lines were maintained in DMEM-F12
culture medium (Gibco BRL, Carlsbad, CA, USA) contain-
ing 10% heat-inactivated foetal bovine serum (FBS) (PAA,
Pasching, Austria). Cells were subcultured twice a week
using a trypsin-EDTA solution (Gibco BRL, Carlsbad, CA,
USA). B16F0 is a C57BL/6 mouse melanoma cell line [10]
while F3II is a mammary carcinoma cell line obtained
from a clonal subpopulation of a spontaneous Balb/c
mouse mammary tumor [11].
RT-PCR
Expression of CMAH mRNA was evidenced by means of
an RT-PCR assay, using total RNA from normal mouse
liver or tumor cell lines as template. Total RNA was
obtained using the RNAqueous Midi RNA kit (Ambion,
Austin, TX, USA) following the manufacturer's instruc-
tions. RT reactions consisted of 5 μg total RNA, 10 mM
dNTPs, 50 ng random hexamers (pd(N)6; GE Healthcare,
Chalfont St. Giles, Buckinghamshire, England) as first
strand primer, 0.1 M DTT, 40 U RNAseOUT (Invitrogen,
Carlsbad, CA, USA) and 200 U Superscript III retrotran-
scriptase (Invitrogen, Carlsbad, CA, USA) in a 20 μl final
volume. RT reactions were performed at 50°C during 1 h.
The CMAH sequence was amplified by means of a PCR
reaction comprised of 45 μl Supermix High Fidelity PCR
mix (Invitrogen, Carlsbad, CA, USA), 10 pmol forward
primer (5'-CGCCTTCCTGGTGTGA-3'), 10 pmol reverse
primer (5'-GTTGGGTGGTGTTAGAGG-3'), and 1 μg
cDNA obtained in the RT step. The amplification profile
consisted of a single initial denaturation step (95°C, 5
min), followed by 35 cycles of 95°C, 30 seg; 53.7°C, 1
min and 72°C, 1.5 min; ending with a final extension step
(72°C, 5 min). PCR reactions yielded the expected 1776
bp amplicon and also another two products with similar
sizes. Accordingly with the publication of Koyama et al.
[12] the expression of this enzyme results in splicing alter-
natives which can explain the alternative bands obtained
in this work.
Monoclonal antibodies
For immunohistochemistry or slot blot assays, the 14F7
monoclonal antibody was employed (gently provided by
the Center of Molecular Immunology, Havana, Cuba).
This murine IgG antibody has demonstrated a specific
reactivity against NeuGc-GM3 ganglioside [13,14]. Addi-
tionally, Krengel et al. carried out a crystal structure anal-
ysis demonstrating that 14F7 specifically recognizes
NeuGc-GM3, but not NeuAc-GM3 [15].
Slot blot assay
Multiwell plates (9.6 cm2/well) were seeded with tumor
cells (5 × 105 cells/well) in DMEM-F12 with 10% FBS.
After 24 h, cells were incubated either with a fixed BSM
concentration (250 μg/ml) during different time spans
(24, 48 or 72 h) or with various BSM concentrations (250
or 125 μg/ml) for 24 h. The cell membrane fraction was
obtained by an adaptation of the technique of Del Pozo et
al. [16]. Briefly, cells were obtained on ice in a hypotonic
buffer containing 10 mM Tris (pH 7.4), 5 mM MgCl2, 5
mM KCl, 1 mM DTT and 1× protease inhibitor cocktail
(Invitrogen, Carlsbad, CA, USA). Cells were mechanically
lysed with a glass homogenizer and centrifuged at 2,000
rpm. The supernatant was centrifuged at 15,000 rpm and
the pellet was washed and resuspended in 100 μl of the
hypotonic buffer. Total proteins were quantified by the
Bradford assay (BioRad, Hercules, CA, USA). Identical
masses of membrane fractions were seeded on a PVDF
membrane (Hybond-P; GE Healthcare, Chalfont St. Giles,
Buckinghamshire, England) previously activated with
methanol and washed with TBS buffer with the aid of the
BIO-DOT SP apparatus (Bio-Rad, Hercules, CA, USA).
Once seeded, membranes were blocked with a 5% low-fat
milk in TBS solution and washed with TBS. Incubation
with the anti-NeuGc-GM3 antibody 14F7 (10 μg/ml) was
performed at room temperature for 1 h. After washingJournal of Experimental & Clinical Cancer Research 2009, 28:146 http://www.jeccr.com/content/28/1/146
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them with TBS-T buffer, membranes were incubated with
the biotinylated anti-mouse antibody (Vector Laborato-
ries, Burlingame, CA, USA) and then incubated with a
streptavidin linked to peroxidase solution (Vector Labora-
tories, Burlingame, CA, USA). Bands were detected by the
ECL method (GE Heathcare, Chalfont St. Giles, Bucking-
hamshire, England) following the manufacturer's instruc-
tions. Membranes were analyzed with the ImageJ analysis
software (National Institute of Health) and the intensity
of each band was recorded and expressed as arbitrary
units.
Indirect immunoperoxidase staining
Tumor cells were cultured for 24 h in chamber-slides
(Nalge-Nunc, Rochester, NY, USA) in serum-free DMEM-
F12 medium containing 250 μg/ml of BSM (Sigma, St.
Louis, MO, USA), and later formalin-fixed. Subsequently,
monolayers were stained by the Vectastain kit (Vector Lab-
oratories, Burlingame, CA, USA) according to the manu-
facturer's instructions. 14F7 mAb was used as primary
antibody at a concentration of 10 μg/ml. Cells were coun-
terstained with hematoxylin.
Adhesion assay
B16 or F3II cells were seeded (40,000 cells/well) in 96-
well plates in D-MEM supplemented with 2 or 5% FBS, in
the presence or absence of 50-100 μg/ml of purified
NeuGc (Sigma, St. Louis, MO, USA). Cells were incubated
at 37°C in a CO2 incubator for 60 min. After incubation,
cells were washed twice with 1× PBS buffer and fixed with
methanol (100 μl/well). After a 10-min incubation, cells
were stained with a 0.1% crystal violet solution (100 μl/
well) for 10 min. After washing thoroughly with distilled
water, 60 μl/well of a 10% methanol-5% acetic acid solu-
tion were added and the plate was shook for a few min-
utes. Absorbance at 595 nm was measured.
Proliferation assay
B16 or F3II cells were seeded (2,500 cells/well) in 96-well
plates in D-MEM supplemented with 1, 5 or 10% FBS, in
the presence or absence of 50-100 μg/ml of purified
NeuGc. Plates were incubated at 37°C in a CO2 incubator
for 72 h. After incubation, cells were treated with MTT (0.5
mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide in PBS buffer; Sigma, St. Louis, MO, USA).
After a 3-h incubation, the supernatant was discarded,
cells were resuspended in DMSO and absorbance was
measured at 570 nm.
In vivo inoculation of BSM or NeuGc-preincubated cells 
into syngeneic mice
Tumor cell suspensions were preincubated with 500 μg/
ml of BSM or 100 μg/ml of NeuGc in culture medium for
1 h and then extensively washed and resuspended. Con-
trol cells were incubated in the same medium without the
addition of BSM or NeuGc. Inbred C57BL/6 and Balb/c
mice were inoculated intravenously with 1 × 105 B16 and
F3II cells, respectively. After 22 days, lungs were collected,
fixed in Bouin's solution, and metastasic foci were
counted under a dissecting microscope. In another set of
experiments, mice were injected subcutaneously with B16
tumor cells preincubated or not with BSM. The time of
appearance of local tumors was monitored by palpation
and further confirmed by histopathology. Tumor size was
measured with a caliper twice a week and tumor diameter
was calculated as the square root of width × length. Ani-
mals were sacrificed 60 days after tumor inoculation or
when they became moribund.
Results
We first checked the expression of CMAH in B16
melanoma and F3II mammary carcinoma cells. To assess
the presence of CMAH mRNA, an RT-PCR assay using
high affinity primers was performed. As expected, normal
liver was positive for CMAH expression, but neither B16
nor F3II cells expressed the gene. When performed on
total RNA from normal liver, the RT-PCR assay yielded 3
distinct products (Fig. 1). After sequencing, all 3 shared a
very high homology with the CMAH gene sequence. The
intermediately-sized amplicon shared a 99% identity with
the CMAH sequence while the other two proved to be
alternatively spliced variants, as reported by Koyama et al
[12].
We then examined the expression of NeuGc in tumor cells
by immunohistochemical staining, using the 14F7 anti-
body reactive against NeuGc-GM3. No expression was
detected under serum-free in vitro culture conditions. On
the contrary, in the presence of FBS both B16 and F3II
cells became clearly positive (Fig. 2A-D), suggesting that
NeuGc can be incorporated from the bovine source.
In order to increase NeuGc density in the cell membrane,
we incubated B16 and F3II cells in vitro with the minor
type of BSM, a mucin fraction with high NeuGc content
Expression of the CMAH mRNA evidenced by RT-PCR Figure 1
Expression of the CMAH mRNA evidenced by RT-
PCR. Lane 1, total RNA from the B16 mouse melanoma cell 
line; lane 2, total RNA from the F3II mouse mammary carci-
noma cell line; lane 3, total RNA from normal mouse liver.Journal of Experimental & Clinical Cancer Research 2009, 28:146 http://www.jeccr.com/content/28/1/146
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[7]. As expected, in vitro cell incubation with NeuGc-rich
BSM changed the ganglioside expression profile of B16
and F3II cells resulting in a significant increase of NeuGc-
GM3 presence in cell membranes, as revealed by slot blot
analysis (Fig. 3A and 3C). The expression was maintained
in mouse tumor cells for at least 48-72 h (Fig. 3B and 3D).
The same result was observed by immunohistochemical
staining with 14F7 antibody on in vitro monolayer cul-
tured cells (Fig. 2E and 2F).
Interestingly, incubation of tumor cells with purified
NeuGc modulates the in vitro behaviour. Tumor cell adhe-
sion showed a significant increase in both cell lines (Fig
4A); while NeuGc addition impacted differently on prolif-
eration, significantly increasing growth in B16 but not in
F3II cells (Fig 4B).
Finally, we evaluated tumorigenicity and lung coloniza-
tion of BSM-preincubated tumor cells in syngeneic mice.
In both mouse models preincubation with NeuGc-rich
BSM significantly enhanced the metastatic ability of
tumor cells, approximately doubling the number of lung
nodules after intravenous cell injection (Table 1). Similar
results were obtained after preincubation with purified
NeuGc. B16 NeuGc-treated cells showed a 65% increase
in lung nodules (Control: 14.5 ± 4.8, NeuGc: 22.3 ± 3.8;
p = 0.14, Mann-Whitney U test), while for F3II NeuGc-
treated cells the number of lung nodules resulted in a
112% increase (Control: 7.3 ± 1.8, NeuGc: 15.5 ± 2.2; p <
0.05, Mann-Whitney U test). Although all animals chal-
lenged in the flank developed subcutaneous tumors, we
observed a rapid tumor take with BSM-preincubated B16
cells. Significant differences were obtained for tumor
latency and size of melanoma tumors. However, preincu-
bation with BSM did not significantly modify tumor
growth rate (Table 2).
Discussion
NeuGc and NeuAc are two of the main sialic acids in
mammals, being the presence of the oxygen atom in the
C-5 position the single difference between them. This
seemingly minor difference is crucial in many aspects of
cellular behaviour and is produced solely by the CMAH
enzyme [5,17]. This enzyme is present in animals from
the deuterostome lineage [18], which includes all higher
mammals. The expression of this particular enzyme is the
reason for NeuGc presence in most murine normal tissues
[19,20]. In humans, an exon deletion/frameshift muta-
tion in the CMAH gene renders the major pathway for
NeuGc production non functional [21].
Sialic acids have been associated with intrinsic receptors
that function as ligands for specific leucocyte receptors
[22,23] or as extrinsic receptors themselves for certain
pathogens [24,25]. The presence of the distinctive oxygen
atom in NeuGc is determinant in the relationship of the
Indirect immunoperoxidase staining of the NeuGc-GM3 ganglioside with 10 μg/ml of 14F7 monoclonal antibody on formalin- fixed B16 (A, B and E) and F3II (C, D and F) monolayers, cultured in the presence (B and D) or absence (A and C) of 10% FBS  or incubated with 250 μg/ml mucin in FBS-free medium for 24 h (E and F) Figure 2
Indirect immunoperoxidase staining of the NeuGc-GM3 ganglioside with 10 μg/ml of 14F7 monoclonal anti-
body on formalin-fixed B16 (A, B and E) and F3II (C, D and F) monolayers, cultured in the presence (B and D) 
or absence (A and C) of 10% FBS or incubated with 250 μg/ml mucin in FBS-free medium for 24 h (E and F). 
Original magnification 1000×.Journal of Experimental & Clinical Cancer Research 2009, 28:146 http://www.jeccr.com/content/28/1/146
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cell with specific molecules or viruses [26,27]. As an exam-
ple, mouse CD22 (Siglec-2), a regulator of B-cell signal-
ling, homeostasis and survival presents high affinity for
NeuGc whereas its affinity for NeuAc is low [23].
Exploring the expression of NeuGc in murine cell lines,
we have found that B16 and F3II cell lines do not express
the CMAH gene and therefore under-express NeuGc in
their cell membranes. Considering that most normal
mouse somatic cells are positive for the expression of this
gene, it is an interesting fact that malignant cells lack such
expression. In cancer, sialic acids are over-expressed as
part of gangliosides in several malignancies and their
involvement in the malignant cell behaviour has been
previously reported [28-30]. The lack of expression of
NeuGc in mouse tumor cells suggests that the silencing of
the CMAH gene is an important step in the cell transfor-
mation process in this specie. Ecsedy et al. [31] reported
that two brain tumor cell lines express this enzyme under
in vivo conditions but not in vitro. However, authors could
not discard potential contamination of in vivo samples
with RNA from lymphoid cells, which have demonstrated
to be positive for CMAH expression [32].
In human cancer, the situation is dramatically different.
Interestingly, considering the null expression of NeuGc in
human somatic cells, the expression of NeuGc-GM3 in
some human tumors was undoubtedly found [33-35]. Yin
et al. reported notable results supporting the idea that
tumor hypoxia could be one of the factors responsible for
the presence of the non-human sialic acids, such as
NeuGc, in human tumors [36].
It is known that cells are able to take in and process exog-
enous sialic acids for their own glycoconjugates [8,9]. In
our work, the cell lines tested were able to express NeuGc-
Detection of NeuGc-GM3 in cell membrane fraction by slot blot assay in B16 (A and B) and F3II (C and D) cells Figure 3
Detection of NeuGc-GM3 in cell membrane fraction by slot blot assay in B16 (A and B) and F3II (C and D) 
cells. A and C, tumor cells were preincubated with different concentrations of NeuGc-rich BSM and processed 24 h later. B 
and D, tumor cells were preincubated with 250 μg/ml of NeuGc-rich BSM and further processed 24, 48 or 72 h after preincu-
bation. In all cases, densitometric analysis was normalized to the respective control. Means ± SEM of at least 3 determinations 
are shown. *p < 0.05, **p < 0.01 (ANOVA contrasted with Dunnet test).
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GM3 when cultured in the presence of serum, suggesting
an active incorporation of the sugar residue from the cul-
ture medium. Taking this fact into account, we incubated
tumor cells with a NeuGc-rich fraction of BSM [7], look-
ing for an increase in NeuGc presence in the cell mem-
brane. Our results show that this strategy renders a
transient increase of NeuGc-GM3 presence in the cell
membrane, indicating endocytosis of BSM components,
with consequent processing and utilization of NeuGc. In
control slots, a slight staining with 14F7 antibody was
observed. As it was demonstrated, this recognition could
be due to the previous acquisition of NeuGc from bovine
serum present in the growth medium during standard cell
culture conditions. Numerous experiments have shown
that mucin expression in tumor cells can enhance malig-
nant behaviour [37,38]. However, there are no reports
showing that these molecules are able to be taken in and
processed by cells. Our results support the idea that cells
are able to process the NeuGc-rich BSM, incorporating
some of their components in the carbohydrate sugar
chains of the plasma membrane. Expression of NeuGc-
GM3 on cell membrane as a consequence of preincuba-
tion with NeuGc-rich culture medium, was demonstrated
also by immunohistochemistry. Results support that
NeuGc present in culture medium can be incorporated
and expressed on the cells either coming from bovine
serum or from mucin.
The altered sugar expression pattern obtained after incu-
bation with NeuGc-rich BSM or purified NeuGc resulted
in promotion of the malignant phenotype. Preincubation
with BSM or NeuGc increased the metastatic ability of
both B16 melanoma and F3II carcinoma cells, and a
reduced melanoma tumor latency by BSM preincubation
was also observed. As it was shown, the presence of
NeuGc in the plasma membrane is maintained in vitro for
no more than two or three days. It is expected that an
equal decline in the expression takes place in vivo. To
explore the impact of NeuGc presence on tumor growth,
we are currently working on the development of CMAH
transfected cell lines in order to obtain a stable NeuGc
expression tumor model. Preliminary results (not shown)
suggested that transfected tumor cells have an increased in
vitro adhesion and proliferation in a similar manner as
mucin or NeuGc-treated cells. Since NeuGc-GM3 is a pos-
tulated tumor antigen in human cancers [39], develop-
ment of NeuGc-positive murine tumor cells allows the
possibility to evaluate cancer vaccines in animal models
[40].
A, adhesion assay Figure 4
A, adhesion assay. B16 or F3II cells were incubated for 1 h 
in medium with 2% FBS, either with (filled bars) or without 
(empty bars) 50 μg/ml of purified NeuGc. Data represent 
mean ± SEM (n = 6). *p < 0.05, **p < 0.01 (t test). B, prolif-
eration assay. B16 (black square) or F3II (black diamond) 
cells were grown for 72 h in medium supplemented with 1, 5 
or 10% FBS, either with or without 100 μg/ml of purified 
NeuGc. Dashed line refers to proliferation in control monol-
ayers without addition of NeuGc. Data represent mean of 6 
determinations; in all cases SEM was less than 5%. ***p < 
0.001 versus the respective control (ANOVA contrasted 
with Tukey-Kramer multiple comparisons test).
Table 1: Experimental lung metastasis in syngeneic mice after 
intravenous injection of B16 melanoma or F3II mammary 
carcinoma cells, preincubated or not with NeuGc-rich BSM.
Treatment Lung metastasisA
(nodules per animal)
B16 cells F3II cells
Control 6.4 ± 2.2 6.2 ± 2.1
BSM-preincubated 11.6 ± 1.5* 13.3 ± 3.1*
ALung nodules were counted 22 days after intravenous injection of 
B16 or F3II cells (1 × 105 cells/mouse). Values represent mean ± SEM 
of at least 10 mice.
*p < 0.05 versus the respective control (Mann-Whitney U test).Journal of Experimental & Clinical Cancer Research 2009, 28:146 http://www.jeccr.com/content/28/1/146
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Considering the results obtained we hypothesize that
NeuGc presence in the cell membrane is actively involved
in the early phases of tumor formation and takes part in
tumor nesting at distant sites.
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